Dexmedetomidine Trial Tests Delirium Prevention After Deep Brain Stimulation in Older Parkinson’s Patients
Postoperative delirium remains one of the most disruptive complications in older adults undergoing neurosurgery, and the risk may be especially consequential in Parkinson’s disease, where baseline cognitive vulnerability, motor impairment, and perioperative medication changes can collide. A new single-center trial in China is built around a simple but clinically important question: can prophylactic dexmedetomidine reduce delirium after deep brain stimulation in elderly patients with Parkinson’s disease?
The study is designed as a randomized, double-blind, placebo-controlled trial and will enroll 292 patients aged 60 years and older who are scheduled for DBS. All participants will be stratified by the operative target — either the subthalamic nucleus or the globus pallidus interna — before random allocation in a 1:1 ratio. The trial is centered at Beijing Tiantan Hospital, and its registration number is NCT05197439.
A single-sentence clinical premise drives the entire protocol: if delirium can be prevented during the first days after DBS, recovery may be smoother and longer-term functional gains may be easier to preserve.
Why Delirium Prevention Matters in DBS for Parkinson’s Disease
DBS can improve motor symptoms in middle and late Parkinson’s disease and may allow reduction of levodopa exposure, which in turn can lessen medication-related adverse effects. Yet the postoperative period can be fragile, particularly in older patients who face anesthetic exposure, surgical stress, sleep disruption, and fluctuating dopaminergic therapy. Delirium in that setting is not a minor inconvenience. It can prolong hospitalization, complicate neurologic assessment, increase care needs, and erode the short-term and long-term quality of life that DBS is intended to improve.
Dexmedetomidine is an appealing candidate for prevention because of its sedative and sympatholytic profile. In perioperative settings, it has been used to calm agitation without the same degree of respiratory suppression seen with some other sedatives. That pharmacologic profile makes it attractive in older neurosurgical patients, where oversedation can obscure neurologic examination and destabilize recovery. The protocol is testing whether those properties translate into fewer delirium episodes after DBS in a Parkinson’s cohort at elevated risk.
Trial Design, Dosing, and Endpoint Assessment
The intervention begins at general anesthesia induction. Patients assigned to the dexmedetomidine arm will receive a continuous infusion at 0.1 µg/kg/hour for 48 hours using an electronic pump. The control arm will receive normal saline at the same rate. The double-blind design is intended to keep clinicians and patients unaware of treatment allocation, reducing the chance that expectations influence delirium assessment or postoperative management.
The trial’s primary endpoint is the incidence of postoperative delirium within 5 days of surgery. Delirium will be assessed using the Richmond Anxiety Scale combined with the Confusion Assessment Method for the intensive care unit, or the 3-minute diagnostic interview for CAM when applicable. The choice of structured bedside tools matters because delirium in postoperative neurosurgical patients can fluctuate hour by hour, making informal observation unreliable.
The protocol also includes several secondary outcomes: adverse events, non-delirium complications, length of stay in the intensive care unit, length of hospital stay, and all-cause 30-day mortality after surgery. Those measures will help distinguish whether any delirium reduction comes with a safety tradeoff or whether the drug improves early recovery without adding downstream harm.
Biological Rationale for the Prophylactic Approach
The logic behind preemptive dexmedetomidine use is rooted in how delirium emerges. Acute brain dysfunction after surgery is rarely caused by a single trigger. In older adults, it often reflects a convergence of neuroinflammation, sleep-wake disruption, hemodynamic stress, pain, polypharmacy, and reduced central reserve. Parkinson’s disease may magnify that vulnerability because the disease itself alters dopaminergic circuits, and perioperative medication adjustments can further destabilize cognition and arousal.
By providing continuous sedation at a low infusion rate during the early postoperative window, dexmedetomidine may help blunt sympathetic activation and reduce agitation, sleep fragmentation, and physiologic stress. In theory, that could limit the cascade that tips susceptible patients into delirium. The investigators are testing that mechanism in a setting where the clinical stakes are high and the patient population is older, neurologically fragile, and already undergoing a major intracranial procedure.
What the Protocol Can and Cannot Answer Yet
Because this is a protocol rather than a completed efficacy study, it does not establish whether dexmedetomidine actually prevents delirium after DBS. It does, however, define a rigorous framework for answering the question under controlled conditions. The sample size of 292 patients suggests a meaningful effort to detect a difference in the primary delirium endpoint, while the stratification by DBS target should help balance a procedural variable that could otherwise confound outcomes.
The protocol also makes clear that safety will remain central. Dexmedetomidine can be useful in the perioperative setting, but any sedative strategy in an elderly neurosurgical population must be judged against adverse events, hemodynamic effects, and the possibility of delaying postoperative assessment. The inclusion of ICU and hospital length of stay, along with 30-day mortality, will help capture whether a delirium-prevention strategy changes the broader recovery trajectory or only a narrow bedside endpoint.
A 48-hour infusion may be enough to bridge the highest-risk postoperative window. That is the practical hypothesis being tested.
Ethics, Oversight, and Pending Dissemination
The protocol has been approved by the Ethics Committee of Beijing Tiantan Hospital of Capital Medical University, under approval number KY2022-003-03. Results will be presented at scientific conferences and published in medical journals once the trial is complete.
For clinicians caring for older patients with Parkinson’s disease, the study addresses a familiar dilemma: DBS can meaningfully improve motor function, yet the postoperative period can still be derailed by delirium. If the trial shows benefit, it could support a relatively simple preventive strategy at the intersection of neurosurgery, anesthesia, and geriatric care. If it does not, the field will still gain a carefully designed test of a biologically plausible approach in a population where delirium prevention remains clinically important and incompletely solved.